Ownership and insider activity for KALA BIO, Inc. (KALA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R.
Price
| Price | $0.52 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $45.5M | $114.6M | $170.9M | $85.4M | $77.3M | $92.1M | $70.5M | $50.9M | $51.2M | $7.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | $76.3M | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | $1.0M | $13.1M | $9.9M | $17.5M | $6.5M | $236000 | 0 | 0 |
| Inventory | 0 | 0 | $4.1M | $4.6M | $5.2M | $8.6M | 0 | 0 | 0 | 0 |
| Total Current Assets | $45.6M | $115.2M | $177.0M | $105.5M | $171.4M | $124.4M | $85.9M | $52.9M | $52.8M | $9.5M |
| Property, Plant & Equipment | $594000 | $786000 | $31.7M | $32.5M | $31.0M | $4.0M | $416000 | $2.8M | $2.4M | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $46.3M | $116.1M | $221.0M | $154.3M | $221.6M | $139.4M | $86.8M | $55.9M | $55.5M | $9.5M |
| Accounts Payable | $997000 | $1.2M | $5.4M | $2.5M | $1.7M | $4.9M | $2.3M | $919000 | $628000 | $986000 |
| Short-term Debt | $556000 | $6.7M | 0 | 0 | 0 | 0 | $5.0M | 0 | $10.3M | 0 |
| Total Current Liabilities | $5.5M | $14.5M | $17.0M | $24.8M | $22.2M | $37.4M | $25.7M | $8.3M | $17.0M | $2.5M |
| Long-term Debt | $9.1M | $12.0M | $70.2M | $71.2M | $72.2M | $78.9M | $37.9M | $34.2M | $20.1M | 0 |
| Total Liabilities | $134.1M | $26.5M | $116.0M | $124.6M | $121.6M | $122.6M | $67.8M | $48.4M | $43.2M | $2.5M |
| Retained Earnings | -$92.1M | -$134.4M | -$201.1M | -$295.5M | -$399.8M | -$542.4M | -$587.2M | -$629.4M | -$667.9M | -$694.9M |
| Total Equity | -$87.8M | $89.7M | $105.0M | $29.7M | $100.0M | $16.8M | $19.0M | $7.5M | $12.3M | $7.0M |
| Total Debt | $9.7M | $18.7M | $99.4M | $101.2M | $100.9M | $80.2M | $43.0M | $36.3M | $32.3M | 0 |
| Net Debt | -$35.8M | -$95.9M | -$71.5M | $15.7M | -$52.6M | -$11.9M | -$27.5M | -$14.6M | -$18.9M | -$7.6M |
| Working Capital | $40.1M | $100.8M | $160.0M | $80.7M | $149.2M | $86.9M | $60.3M | $44.5M | $35.8M | $7.0M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 6.88 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -60.75 |
Profitability
| Return on Equity | -222.32% |
| Return on Invested Capital | -232.05% |
| Return on Assets | -95.26% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABP · AIM · CANF · ENSC · IBO · KTTA · OGEN
Explore sector: Healthcare · Biotechnology
More sections of KALA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks